CAMBRIDGE, Mass., April 8, 2026
Anumana, Inc. has received U.S. FDA clearance for its ECG-AI™ algorithm designed to detect cardiac amyloidosis using standard 12-lead electrocardiograms, marking a major advancement in AI-driven cardiovascular diagnostics and early disease detection. This milestone establishes the solution as the first and only FDA-cleared AI tool for identifying cardiac amyloidosis through routine ECG data, enabling clinicians to detect a life-threatening condition earlier and more accurately at the point of care.
AI-Powered ECG Algorithm Enables Early Detection
Anumana’s ECG-AI™ algorithm represents a breakthrough in software-as-a-medical-device (SaMD) innovation, leveraging artificial intelligence to analyze ECG waveforms and identify subtle patterns associated with cardiac amyloidosis that are often missed by human interpretation. The technology integrates seamlessly into existing clinical workflows, utilizing routine ECG tests already performed in clinical settings, thereby eliminating the need for additional diagnostic procedures.
Cardiac amyloidosis is a serious and often underdiagnosed condition caused by abnormal protein deposits in the heart, which can lead to heart failure if not detected early. Due to overlapping symptoms with common cardiovascular diseases, diagnosis is frequently delayed. By enabling earlier identification, the ECG-AI™ tool supports timely clinical intervention and improved patient outcomes, addressing a critical unmet need in cardiovascular care.
Strong Clinical Validation Demonstrates High Accuracy
Advertisement
The FDA clearance is supported by robust clinical validation from a large, multicenter study involving over 25,000 patients across four U.S. health systems, demonstrating the algorithm’s strong diagnostic performance. The ECG-AI™ model achieved 78.9% sensitivity and 91.2% specificity, highlighting its ability to accurately identify patients at risk for cardiac amyloidosis.
This high level of accuracy enables clinicians to optimize the use of confirmatory testing and prioritize high-risk patients, improving diagnostic efficiency and reducing unnecessary procedures. The model was validated across both ATTR and AL forms of cardiac amyloidosis, ensuring broad applicability in clinical practice.
Additionally, the algorithm was initially developed at the Mayo Clinic and underwent extensive real-world validation, reinforcing its scientific credibility and clinical reliability. The FDA clearance further builds on its earlier Breakthrough Device Designation and inclusion in the FDA’s Total Product Life Cycle Advisory Program, underscoring its importance in advancing medical innovation.
Expanding Role of AI in Cardiovascular Diagnostics
The approval of Anumana’s ECG-AI™ algorithm highlights the growing role of artificial intelligence in transforming cardiovascular diagnostics and clinical decision-making. By enabling clinicians to extract more value from existing diagnostic tools, AI-driven solutions are helping to improve efficiency, accuracy, and patient care outcomes.
Anumana continues to expand its portfolio of FDA-cleared ECG-AI algorithms, including solutions for low ejection fraction and pulmonary hypertension, with additional applications under development. This strategy reflects a broader vision of integrating multimodal AI technologies across the continuum of cardiovascular care, from early detection to treatment guidance.
The ability to detect multiple conditions from a single ECG test represents a paradigm shift in diagnostic medicine, where AI enhances traditional tools to deliver more comprehensive insights. As adoption of such technologies grows, they are expected to play a key role in improving clinical workflows, reducing diagnostic delays, and enhancing patient outcomes globally.
Anumana’s FDA clearance for its ECG-AI™ cardiac amyloidosis algorithm marks a significant milestone in AI-enabled healthcare innovation, providing clinicians with a powerful tool to detect a complex and often overlooked disease earlier. With its high diagnostic accuracy, seamless integration, and strong clinical validation, the technology is poised to transform cardiovascular diagnostics and support better patient care, reinforcing the critical role of AI in the future of medicine.
Source: Anumana press release
